Assembly Biosciences (ASMB) Cash & Current Investments (2010 - 2026)

Assembly Biosciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $226.6 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 148.94% year-over-year to $226.6 million in Q1 2026; TTM through Mar 2026 was $226.6 million, a 148.94% increase from a year earlier, with the FY2025 full-year figure at $248.1 million, up 121.37% from the prior year.
• Cash & Current Investments retreated to $226.6 million in Q1 2026 per ASMB's latest filing, from $248.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $248.1 million in Q4 2025 and bottomed at $46.2 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $109.2 million (2024), against an average of $120.7 million.
• Across the five-year window, Cash & Current Investments plunged 57.47% in 2023 and surged 148.94% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $91.6 million in 2022, then soared by 42.18% to $130.2 million in 2023, then slipped by 13.95% to $112.1 million in 2024, then jumped by 121.37% to $248.1 million in 2025, then retreated by 8.67% to $226.6 million in 2026.
• Per Business Quant, the three latest ASMB Cash & Current Investments figures stand at $226.6 million (Q1 2026), $248.1 million (Q4 2025), and $232.6 million (Q3 2025).